Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis

Direct‐acting antivirals (DAAs) are currently available even for patients with decompensated cirrhosis. Reportedly, hepatic functional reserve improved in the short term after achievement of sustained virologic response (SVR). We aimed to clarify the outcomes after achievement of SVR in patients with decompensated cirrhosis who were treated by DAAs in real‐world clinical practice.

[1]  M. Kurosaki,et al.  Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group , 2021, Journal of medical virology.

[2]  K. Matsuura,et al.  Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response , 2021, Hepatology communications.

[3]  Yoshiyuki Suzuki,et al.  Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study , 2021, BMC Gastroenterology.

[4]  K. Chayama,et al.  Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus , 2021, Infectious Diseases and Therapy.

[5]  Y. Shibasaki,et al.  Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  K. Iwakiri,et al.  Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. , 2021, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[7]  Kouichi Miura,et al.  Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  H. Yoshiji,et al.  Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study , 2020, Journal of Gastroenterology.

[9]  M. Imamura,et al.  Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  N. Hotta,et al.  Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study , 2020, Infectious Diseases and Therapy.

[11]  A. Tanaka.  Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  N. Hotta,et al.  The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study , 2020, Hepatology International.

[13]  S. Asch,et al.  Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents , 2020, Hepatology.

[14]  Y. Takei,et al.  Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema , 2019, Journal of gastroenterology and hepatology.

[15]  M. Nakao,et al.  Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  J. Mar,et al.  Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments , 2019, Expert review of gastroenterology & hepatology.

[17]  N. Hotta,et al.  The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study , 2019, Alimentary pharmacology & therapeutics.

[18]  A. Tsubota,et al.  Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan , 2019, Open forum infectious diseases.

[19]  G. Ioannou,et al.  What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? , 2019, Gastroenterology.

[20]  Giovanni Raimondo,et al.  Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.

[21]  M. Manns,et al.  Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. , 2018, Gastroenterology.

[22]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[23]  A. Walker,et al.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[24]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[25]  M. Kumar,et al.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing , 2016, Hepatology International.

[26]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[27]  M. Pedrosa,et al.  Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  H. Wedemeyer,et al.  Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies , 2015, Alimentary pharmacology & therapeutics.

[29]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[30]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[31]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.